
    
      An open-label, randomized, comparative, parallel group study to assess the Immunogenicity of
      Lupin's Peg-filgrastim versus Neulasta® as an Adjunct to Chemotherapy in Patients with Breast
      Cancer

      Primary Objective: To assess the immunogenicity of Lupin's Peg-filgrastim with Neulasta® in
      patients with breast cancer.

      Secondary Objectives: To assess the safety of Lupin's Peg-filgrastim with Neulasta® in
      patients with breast cancer
    
  